Li and collaborators analysed mutations in BALs, finding that the combined detection of mutations on KRAS and TP53 yielded a sensitivity of 66% for the diagnosis of peripheral nonsmall cell lung cancer (Li et al., 2014). The gene discussed is KRAS; the disease is lung cancer.